Results 91 to 100 of about 37,430 (216)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma

Case Reports in Hematology, 2019
A 74-year-old male with diffuse large B-cell lymphoma, with an Ann Arbor stage IV-A, was submitted to immune-chemotherapy in 2014, with complete remission of the disease.
R. Palmieri, F. Esposito, F. Meconi, V. M. Rapisarda, L. Anemona, G. Paterno, S. Vaccarini, D. Nasso, L. Pupo, M. Cantonetti   +9 more
doaj   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Differential effects of lenalidomide during plasma cell differentiation [PDF]

, 2016
International audienceThalidomide, lenalidomide and pomalidomide have greatly improved the outcome of patients with multiple myeloma. However, their effects on plasma cells, the healthy counterpart of myeloma cells, are unknown.
Ceballos, Patrice, Ceballos, P, Vincent, Laure, Duperray, C, Chopra, Rajesh, Cren, Maïlys, Moreaux, J, Duperray, Christophe, Cartron, Guillaume, Rossi, Jean-François, Robert, Nicolas, Klein, Bernard, Schafer, P, Chopra, R, Schäfer, Peter, A, Klein, B, Cren, M, Schäfer, Peter,, Rossi, J-F, Jourdan, M, Vincent, L, Cartron, G, Jourdan, Michel, Moreaux, Jerome, Robert, N   +24 more
core   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Advances in Hematology, 2012
Although multiple myeloma remains incurable outside of allogeneic hematopoietic stem cell transplantation, novel agents made available only in the last few decades have nonetheless tremendously improved the landscape of myeloma treatment.
S. A. Tuchman, N. J. Chao, C. G. Gasparetto   +2 more
doaj   +1 more source

Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta‐analysis

British Journal of Haematology, EarlyView.
Veer Shah, Darshi Shah, Payton Utzman, Karan Shah, Srivatsan Swaminathan, Maria Mainou, Rajshekhar Chakraborty, Aaron Goodman, Samer Al Hadidi, Amar H. Kelkar, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin   +11 more
wiley   +1 more source

Patient and Healthcare Provider Satisfaction With Subcutaneous Versus Intravenous Administration of Daratumumab in Combination With Lenalidomide and Dexamethasone as First‐Line Treatment in Patients With Newly Diagnosed Non‐Transplant Eligible Multiple Myeloma: Final Results of the MYLENE Study

European Journal of Haematology, EarlyView.
ABSTRACT Objectives The MYLENE non‐interventional study (NIS) aimed to close the gap in real‐world data on the experience and satisfaction with subcutaneous (sc) and intravenous (iv) daratumumab application in patients with newly diagnosed non‐transplant eligible multiple myeloma in Germany.
Eyck von der Heyde, Marcel Reiser, Vanessa Baumgartner, Christian Englisch, Oliver Frank, Sabrina Buchholz, Fabian Kreimendahl, Jens Uhlig, Dieter Bürkle, Wolfgang Knauf   +9 more
wiley   +1 more source

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

Haematologica, 2009
Clonal heterogeneity has not been described in patients with myelodysplastic syndrome with isolated del(5q), for which lenalidomide has emerged as a highly potent treatment.
Martin Jädersten, Leonie Saft, Andrea Pellagatti, Gudrun Göhring, James S. Wainscoat, Jacqueline Boultwood, Anna Porwit, Brigitte Schlegelberger, Eva Hellström-Lindberg   +8 more
doaj   +1 more source

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

British Journal of Haematology, EarlyView.
Claire Comerford, Patrick J. Hayden, Diderik‐Jan Eikema, Linda Koster, Sandra Sauer, Annoek Broers, Neil Rabin, Jean Noel Bastie, Tobias Gedde‐Dahl, Luisa Giaccone, Deborah Richardson, Kristina Carlson, Britta Besemer, Jean‐Marc Schiano de Colella, Robert Zeiser, Laure Vincent, Thomas Pabst, Anne Cairoli, Christine Schuermans, Monica Poiani, Kavita Raj, Joanna Drozd‐Sokolowska, Laurent Garderet, Inas El Najjar, Meral Beksac, Donal P. McLornan   +25 more
wiley   +1 more source